As of April 30, at least 67 suspected cases of thrombosis have been reported in Germany after vaccination with the COVID-19 Vaxzevria vaccine from the British-Swedish company AstraZeneca. This is according to a new report from the Paul Ehrlich Institute for Vaccine Development and Biomedical Medicines (PEI, the German regulator).
It is noted that the majority of cases (67%) involved dura sinus thrombosis. At least 14 people died, including nine women and five men. Such data, citing the organization leads on Friday, May 7.
Earlier, on April 9, it became known that 42 cases of a specific form of a very rare cerebral vein thrombosis as a result of vaccination with the drug Vaxzevria were registered in Germany. It was noted that, for the most part, the thrombosis was detected in women. Their ages ranged from 20 to 63 years.
On March 18, the Pharmacovigilance Risk Assessment Committee, together with an expert from the aforementioned Institute and representatives of national agencies from the European Union (EU), held a meeting to assess the side effects of the AstraZeneca vaccine. The meeting concluded that the benefits of the vaccine in controlling the spread of COVID-19 outweigh the risk of side effects caused by it.